Day: November 3, 2022

Rychnovsky, Scott D.; Powers, Jay P. published an article in 2001, the title of the article was Zinc/copper couple.SDS of cas: 38838-06-1 And the article contains the following content:

Properties and applications of zinc/copper couple, an activated form of zinc metal reagent that can be used for cyclopropanation and conjugate addition of alkyl iodides to enones are reviewed. Also used for preparation of dichloroketene and 2-oxyallyl cations for cycloaddition reactions. The experimental process involved the reaction of (3aS,4S,6R,6aR)-4-(Iodomethyl)-6-methoxy-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxole(cas: 38838-06-1).SDS of cas: 38838-06-1

The Article related to review zinc copper couple preparation property reactivity, Organometallic and Organometalloidal Compounds: Reviews and other aspects.SDS of cas: 38838-06-1

Referemce:
1,3-Benzodioxole – Wikipedia,
Dioxole | C3H4O2 – PubChem

On February 3, 2005, Fryszman, Olga M.; Lang, Hengyuan; Lan, Jiong; Chang, Edcon; Fang, Yunfeng published a patent.Application In Synthesis of Methyl 3-(1,3-dioxolan-2-yl)benzoate The title of the patent was Preparation of 5-membered heterocycles, in particular pyrazoles and imidazoles, as p38 kinase inhibitors. And the patent contained the following:

Title compounds I of [wherein R1 = H, acyl, P(:O)(OH)2; R2 = H, halo, (un)substituted alkyl, alkylthio, alkylsulfinyl, etc.; G = hetero/aryl, aralkyl, cycloalkyl, etc.; B = hetero/aryl; A = 5-membered ring containing one or two heteroatoms in the ring; D = CONH2 and derivatives, (un)substituted heteroaryl; R5 = H, halo, halo/thio/alkyl, OH and derivatives, alkyl/amino, etc.; R6 = H, halo, alkyl, alkoxy; and their pharmaceutically acceptable derivatives] were prepared as p38 kinase, including p38α and p38β kinase, inhibitors. Thus, reacting 3-hydrazino-N-methoxy-4-methylbenzamide with NaNO2 in the presence of SnCl2, and cyclization of the hydrazine with 2-(3-iodobenzoyl)-3-phenylaminoacrylonitrile gave II. Selected I displayed IC50 values <1 μM in a p38α kinase inhibition assay. I are useful for the treatment, prevention, or amelioration of one or more symptoms of p38 kinase mediated diseases and disorders, e.g. inflammatory disease, autoimmune disease, etc. The experimental process involved the reaction of Methyl 3-(1,3-dioxolan-2-yl)benzoate(cas: 124038-36-4).Application In Synthesis of Methyl 3-(1,3-dioxolan-2-yl)benzoate

The Article related to imidazole preparation p38 kinase inhibitor inflammation immunomodulator, antiinflammatory agent pyrazole preparation p38 kinase inhibition autoimmune disease, Heterocyclic Compounds (More Than One Hetero Atom): Imidazoles and other aspects.Application In Synthesis of Methyl 3-(1,3-dioxolan-2-yl)benzoate

Referemce:
1,3-Benzodioxole – Wikipedia,
Dioxole | C3H4O2 – PubChem

On December 31, 2016, Ajay, Sama; Arora, Inderpreet; Saidhareddy, Puli; Shaw, Arun K. published an article.COA of Formula: C9H15IO4 The title of the article was Diversity-Oriented Synthesis of cis-3,4-Dihydroxylated Piperidine and Its Higher Saturated and Unsaturated Homologues from D-Ribose and Their Glycosidase-Inhibition Study. And the article contained the following:

The synthesis of six-, seven-, and eight-membered cis-dihydroxy azacycles has been accomplished from D-ribose using Vasella reductive amination as a key step and utilization of hydroboration-oxidation, Mitsunobu reaction, and ring-closing metathesis (RCM) reactions in a facile manner. These homologous dihydroxylated heterocyclic scaffolds were subjected to the glycosidase inhibition assays. However, only a moderate inhibitory activity for three out of five compounds was observed against α-glucosidases with a high degree of selectivity. The experimental process involved the reaction of (3aS,4S,6R,6aR)-4-(Iodomethyl)-6-methoxy-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxole(cas: 38838-06-1).COA of Formula: C9H15IO4

The Article related to cis dihydroxy azacycle preparation glycosidase inhibitor, ribose reductive amination hydroboration oxidation mitsunobu ring closing metathesis, Heterocyclic Compounds (One Hetero Atom): Higher-Membered Rings and other aspects.COA of Formula: C9H15IO4

Referemce:
1,3-Benzodioxole – Wikipedia,
Dioxole | C3H4O2 – PubChem

On December 12, 2003, Verhelst, Steven H. L.; Martinez, Baltasar Paez; Timmer, Mattie S. M.; Lodder, Gerrit; Van der Marel, Gijsbert A.; Overkleeft, Herman S.; Van Boom, Jacques H. published an article.Synthetic Route of 38838-06-1 The title of the article was A Short Route toward Chiral, Polyhydroxylated Indolizidines and Quinolizidines. And the article contained the following:

In this paper, a rapid route toward functionalized bicyclic alkaloids is presented. In only three steps, an easily accessible carbohydrate derivative was converted into iodomethyl indolizidine I, which can equilibrate to the corresponding iodoquinolizidine II. We provide strong evidence that this equilibration proceeds via an aziridinium ion intermediate. Furthermore, nucleophilic substitution of the iodomethyl indolizidine as well as the aziridinium intermediate gives access to highly functionalized indolizidine and quinolizidine alkaloids. The experimental process involved the reaction of (3aS,4S,6R,6aR)-4-(Iodomethyl)-6-methoxy-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxole(cas: 38838-06-1).Synthetic Route of 38838-06-1

The Article related to chiral polyhydroxylated indolizidine quinolizidine preparation, Alkaloids: Alkaloids Containing One Nitrogen Atom At A Bridgehead and other aspects.Synthetic Route of 38838-06-1

Referemce:
1,3-Benzodioxole – Wikipedia,
Dioxole | C3H4O2 – PubChem

On June 12, 2014, Rancati, Fabio; Linney, Ian; Knight, Chris; Schmidt, Wolfgang published a patent.Synthetic Route of 124038-36-4 The title of the patent was Preparation of compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity. And the patent contained the following:

The present invention relates to compounds I [wherein: Q is a group of formula Q1, Q2 and Q3; Z is H or OH; Y is selected from A1B(CH2)n1A2CD(CH2)mE and A1CBC’D(CH2)pE, which are divalent groups; wherein A1 and A2 are independently absent or are selected from the group consisting of C1-6-alkylene, C3-8-cycloalkylene and C3-8-heterocycloalkylene optionally substituted by one or more substituents selected from the group consisting of C1-6-alkyl, aryl-(C1-6-alkyl) and heteroaryl-(C1-6-alkyl);]. [B is absent or is selected from the group consisting of C3-8-cycloalkylene, C3-8-heterocycloalkylene, arylene and heteroarylene, optionally substituted by one or more groups selected from halogens, CN, linear or branched C1-6-alkyl, linear or branched C1-6-haloalkyl, C1-6-alkoxy, aryl, aryl-(C1-6-alkyl), NR7R8 and heteroaryl;C and C’ are absent or are independently selected from the group consisting of oxygen, C(:O), OC(:O) and -C(OO)- or one of the following:]. [NR7C(:O), O(CH2)nO2C, N((CH2)nCO2R7)SO2, NR7(CH2)nO2C, CO2(CH2)nNR7C(:O), N(COR7)(CH2)nO2C, O2CCR7R8NHC(:O), NR7CONR7′(CH2)nO2C, C(:O)NR7(CH2)nO2C, (CH2)O2C, SO2NR7(CH2)nO2C, C12, N(SO2R7)(CH2)nO2C, C14; wherein R7, R7′ and R8 are independently H or selected from the group consisting of linear or branched C1-6-alkyl, C3-8-cycloalkyl, (C3-8-cycloalkyl)-(C1-6-alkyl), (C3-8-heterocycloalkyl)-(C1-6-alkyl), aryl and aryl-(C1-6-alkyl), optionally substituted by one or more substituents selected from the group consisting of C1-6-alkyl, C1-6-haloalkyl, halogen atoms, C1-6-alkoxy and C1-6-alkoxy;]. [D is absent or is selected from the group consisting of C1-6-alkylene, arylene, heteroarylene and C3-8-heterocycloalkylene, optionally substituted by one or more C1-6-alkyl groups; n, n’, m and p are independently O or an integer from 1 to 3; E is absent or is selected from O and OC(:O); G is arylene optionally substituted by one or more substituents selected from the group consisting of halogen atoms, OH, oxo (:O), SH, NO2, CN and NH2;]. [R1 and R2 are independently H or selected from the group consisting of C1-6-alkyl and aryl, optionally substituted by one or more halogen atoms; M is NR3; R3 is H or C1-6-alkyl; R4 is a group of formula J1] acting both as muscarinic receptor antagonists and beta2 adrenergic receptor agonists. Thus, 8-hydroxyquinolin-2-one derivative II was prepared from 3-hydroxybenzophenone via reductive amination with formamide; hydrolysis with HCl in MeOH; N-alkoxycarbonylation with di(tert-butyl) dicarbonate in CH2Cl2 containing EtN(CHMe2)2 followed by treatment with K2CO3 in MeOH; chromatog. resolution with CHIRALPAK® AD; etherification with 4-BrCH2C6H4CO2Me in MeCN containing K2CO3; hydrolysis with HCl in dioxane/MeOH; alkoxycarbonylation with (R)-quinuclidin-3-yl chloroformate (III) in pyridine;. Saponification with aqueous LiOH in THF; amidation with 3-(1,3-dioxolan-2-yl)propyl piperidine-4-carboxylate hydrochloride (IV·HCl) in DMF containing EtN(CHMe2)2 and HATU; deacetalation with aqueous HCl in THF; and reductive amination with of (R)-5-(2-amino-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one hydrochloride (V·HCl) in MeOH containing NaBH(OAc)3 and AcOH. The present invention also relates to processes for their preparation, to compositions comprising them, to therapeutic uses and combinations with other pharmaceutical active ingredients. The receptor activity of I was determined [the Ki values (calculated from IC50 values by the Cheng and Prusoff equation) of most of the compounds of the examples are less than 10 nM in the M3 Receptor and in the β2 adrenoceptor radioligand binding assays]. The experimental process involved the reaction of Methyl 3-(1,3-dioxolan-2-yl)benzoate(cas: 124038-36-4).Synthetic Route of 124038-36-4

The Article related to muscarinic receptor antagonist, beta2 adrenergic receptor agonist, Alkaloids: Alkaloids Containing One Nitrogen Atom At A Bridgehead and other aspects.Synthetic Route of 124038-36-4

Referemce:
1,3-Benzodioxole – Wikipedia,
Dioxole | C3H4O2 – PubChem

On June 12, 2014, Rancati, Fabio; Linney, Ian published a patent.Application of 124038-36-4 The title of the patent was Preparation of compounds having muscarinic receptor antagonist and β2 adrenergic receptor agonist activity. And the patent contained the following:

The present invention relates to the preparation of heterocyclic containing quinuclidine ester compounds acting both as muscarinic receptor antagonists and β2 adrenergic receptor agonists. For example, compound I was prepared in several steps via the coupling of alc. II with acid III. The experimental process involved the reaction of Methyl 3-(1,3-dioxolan-2-yl)benzoate(cas: 124038-36-4).Application of 124038-36-4

The Article related to quinuclidine ester preparation muscarinic receptor antagonist, adrenergic receptor agonist quinuclidine ester, Alkaloids: Alkaloids Containing One Nitrogen Atom At A Bridgehead and other aspects.Application of 124038-36-4

Referemce:
1,3-Benzodioxole – Wikipedia,
Dioxole | C3H4O2 – PubChem

On April 1, 2011, Brock, E. Anne; Davies, Stephen G.; Lee, James A.; Roberts, Paul M.; Thomson, James E. published an article.Computed Properties of 38838-06-1 The title of the article was Asymmetric Synthesis of Polyhydroxylated Pyrrolizidines via Transannular Iodoamination with Concomitant N-Debenzylation. And the article contained the following:

The doubly diastereoselective “matched” conjugate addition of lithium (R)-N-but-3-enyl-N-(α-methyl-p-methoxybenzyl)amide to tert-Bu (4S,5R,E)-4,5-O-isopropylidene-2,7-dienoate (derived from D-ribose in 3 steps) and in situ enolate oxidation with (-)-camphorsulfonyloxaziridine was followed by ring-closing metathesis with Grubbs I to give a hexahydroazocine scaffold. Subsequent treatment with I2 resulted in transannular iodoamination accompanied by loss of the α-methyl-p-methoxybenzyl group to give the corresponding pyrrolizidine scaffold as a single diastereoisomer upon direct crystallization from the crude reaction mixture Further functional group manipulations enabled the preparation of (-)-7a-epi-hyacinthacine A1 (I). The experimental process involved the reaction of (3aS,4S,6R,6aR)-4-(Iodomethyl)-6-methoxy-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxole(cas: 38838-06-1).Computed Properties of 38838-06-1

The Article related to enantioselective synthesis polyhydroxylated pyrrolizidine iodoamination debenzylation, hyacinthacine a1 enantioselective synthesis, Alkaloids: Alkaloids Containing One Nitrogen Atom At A Bridgehead and other aspects.Computed Properties of 38838-06-1

Referemce:
1,3-Benzodioxole – Wikipedia,
Dioxole | C3H4O2 – PubChem

On November 30, 2003, Abdel-Rahman, Adel A.-H.; Abdel-Megied, Ahmed E.-S.; Goda, Adel E.-S.; Zeid, Ibrahim F.; El Ashry, El Sayed H. published an article.Recommanded Product: (3aS,4S,6R,6aR)-4-(Iodomethyl)-6-methoxy-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxole The title of the article was Synthesis and Anti-HBV Activity of Thiouracils Linked via S and N-1 to the 5-Position of Methyl β-D-Ribofuranoside. And the article contained the following:

Reverse nucleoside derivatives of 2-(methylsulfanyl)uracils, e.g. I (RR = CMe2), were prepared by treating of the sodium salt of 2-(methylsulfanyl)uracils with Me 2,3-O-isopropylidene-5-O-p-toluenesulfonyl-β-D-ribofuranoside. The alkylation of 2-thiouracils with Me 5-deoxy-5-iodo-2,3-O-isopropylidene-D-ribofuranoside afforded the corresponding S-ribofuranoside derivatives which were deprotected to give nucleoside analogs, e.g. II (R = H). The Anti-HBV activity of selected compounds was studied. I (R = H) was found to be active against HBV replication with IC50 = 90 μM and CC50 > 100 μM. The experimental process involved the reaction of (3aS,4S,6R,6aR)-4-(Iodomethyl)-6-methoxy-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxole(cas: 38838-06-1).Recommanded Product: (3aS,4S,6R,6aR)-4-(Iodomethyl)-6-methoxy-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxole

The Article related to nucleoside analog synthesis antiviral hbv human, Carbohydrates: Nucleosides and Nucleotides, Cobalamins, Riboflavin and other aspects.Recommanded Product: (3aS,4S,6R,6aR)-4-(Iodomethyl)-6-methoxy-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxole

Referemce:
1,3-Benzodioxole – Wikipedia,
Dioxole | C3H4O2 – PubChem

On February 29, 2000, Maria, Edmilson Jose; Da Silva, Adilson David; Fourrey, Jean-Louis published an article.Safety of (3aS,4S,6R,6aR)-4-(Iodomethyl)-6-methoxy-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxole The title of the article was A radical-based strategy for the synthesis of higher homologues of sinefungin. And the article contained the following:

Homosinefungin, which can be considered an analog of S-adenosylmethionine (SAM) and of S-adenosylhomocysteine (SAH), has been synthesized by means of a sequence in which the key step was the addition of a radical, produced by the simple treatment of an iodide precursor with a zinc-copper couple, to suitably activated olefins. The experimental process involved the reaction of (3aS,4S,6R,6aR)-4-(Iodomethyl)-6-methoxy-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxole(cas: 38838-06-1).Safety of (3aS,4S,6R,6aR)-4-(Iodomethyl)-6-methoxy-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxole

The Article related to sinefungin analog preparation homolytic addition, homosinefungin preparation radical addition, Carbohydrates: Nucleosides and Nucleotides, Cobalamins, Riboflavin and other aspects.Safety of (3aS,4S,6R,6aR)-4-(Iodomethyl)-6-methoxy-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxole

Referemce:
1,3-Benzodioxole – Wikipedia,
Dioxole | C3H4O2 – PubChem

On June 13, 2019, Verhoeven, Jonas; Verniest, Guido Alfons F.; Thuring, Johannes Wilhelmus John F.; Wu, Tongfei; Pande, Vineet; Meerpoel, Lieven; Brehmer, Dirk; Sun, Weimei; Denmark, Scott E. published a patent.Quality Control of (3aS,4S,6R,6aR)-4-(Iodomethyl)-6-methoxy-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxole The title of the patent was Preparation of spirobicyclic nucleoside analogs as PRMT5 enzyme inhibitors. And the patent contained the following:

Spirobicyclic analogs I, wherein R1 and R2 are independently H, acyl; X is H; Y is O, CH2, CF2; Q1 is substituted C; Q2 is N or substituted C; R3a is H, halo, substituted amine, alkyl, alkenyl, cycloalkyl, OH, O-alkyl; L is CH2, O-CH2, CH2-O, O; R5 is Ph, aryl, monocyclic heterocycle, bicyclic heterocycle; and in case L is O or O-CH2, R5 can also represent H; were prepared and used as PRMT5 inhibitors. Thus, spirobicyclic nucleoside II was prepared as PRMT5 enzyme inhibitor and antitumor agent. The experimental process involved the reaction of (3aS,4S,6R,6aR)-4-(Iodomethyl)-6-methoxy-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxole(cas: 38838-06-1).Quality Control of (3aS,4S,6R,6aR)-4-(Iodomethyl)-6-methoxy-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxole

The Article related to spirobicyclic nucleoside preparation prmt5 inhibitor methyltransferase protein arginine antitumor, Carbohydrates: Nucleosides and Nucleotides, Cobalamins, Riboflavin and other aspects.Quality Control of (3aS,4S,6R,6aR)-4-(Iodomethyl)-6-methoxy-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxole

Referemce:
1,3-Benzodioxole – Wikipedia,
Dioxole | C3H4O2 – PubChem